AbbVie (NYSE: ABBV) today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances in research across multiple blood cancers including ...
An update from Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) is now available.
Researchers from the Institute of Human Virology (IHV) at the University of Maryland School of Medicine have discovered how a ...
Researchers from the Institute of Human Virology (IHV) at the University of Maryland School of Medicine have discovered how a ...
Dana-Farber Cancer Institute will present more than 120 oral and poster presentations at the 67th American Society for ...
Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell ...
Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN).BPDCN is a highly aggressive, orphan he ...
Detailed price information for Dianthus Therapeutics Inc (DNTH-Q) from The Globe and Mail including charting and trades.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy classified by WHO and marked by cutaneous lesions, bone marrow infiltration, and CNS involvement.
Zacks Investment Research on MSN
AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?
AbbVie’s ABBV reported third-quarter 2025 results on Oct. 31, before market open. The company beat estimates for both ...
One Connecticut kid undergoing cancer treatment just received a huge gift, thanks to a Wilton nonprofit. Elijah Randolph, 13, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback